세계의 셀리악병 시장 보고서(2025년)

Celiac Disease Global Market Report 2025

US $ 4,490 ￦ 6,310,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,121,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,932,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

셀리악병 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상되며, 2029년에는 10.1%의 CAGR로 11억 5,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 맞춤형 의료에 대한 수요 증가, 의료 인프라 확대, 영양 상담 서비스에 대한 수요 증가, 소아과 진료율 증가, 조기 검진 및 예방 조치에 대한 관심 증가 등에 기인할 것으로 보입니다. 이 기간 동안 예상되는 주요 동향으로는 진단 검사의 가용성 확대, 유전자 검사 기술의 발전, 일차 진료에서 선별검사 프로토콜 강화, ELISA 및 혈청학적 검사법의 혁신, 비침습적 진단 접근법의 채택 등이 있습니다.

맞춤형 의료의 확대는 향후 몇 년 동안 셀리악병 시장의 성장에 크게 기여할 것으로 예상됩니다. 맞춤의료는 개인의 유전적 체질, 환경, 라이프스타일에 맞게 의료를 조정하는 헬스케어 접근법입니다. 맞춤의료에 대한 수요가 증가하는 배경에는 유전자 검사에 대한 접근성이 높아지고 있기 때문입니다. 셀리악병과 관련하여, 맞춤의료는 유전자 마커와 특정 면역반응을 정확하게 파악할 수 있게 하여 보다 표적화되고 효과적인 치료전략을 가능하게 합니다. 예를 들어, 2024년 2월 미국 비영리단체인 개인맞춤의료연합(Personalized Medicine Coalition)은 FDA가 2023년 16건의 희귀질환에 대한 맞춤형 치료제를 승인했으며, 이는 2022년 6건에서 증가한 수치라고 보고했습니다. 이처럼 맞춤형 의료의 성장은 셀리악병 시장을 발전시킬 것으로 예상됩니다.

셀리악병 시장의 주요 기업들은 항 인터류킨 15(IL-15) 항체 등 과도한 면역 세포의 활동을 조절하여 조직 손상을 최소화하는 첨단 치료법 개발에 주력하고 있습니다. 항인터류킨15(IL-15) 항체는 IL-15 사이토카인의 작용을 억제하는 표적 단백질로, 이를 통해 면역반응을 조절하고 염증을 억제하는 데 도움을 주고 있습니다. 예를 들어, 2025년 5월 이스라엘에 본사를 둔 제약회사 테바 파마슈티컬 인더스트리즈(Teva Pharmaceutical Industries)는 미국 식품의약국(FDA)이 항인터류킨 15(IL-15) 항체 TEV-53408을 임상시험용 의약품으로 패스트트랙으로 지정했다고 발표했습니다. TEV-53408은 글루텐을 제거한 식단을 준수하고 있음에도 불구하고 증상이 지속되는 셀리악병 환자를 대상으로 개발되고 있으며, TEV-53408은 셀리악병 장 질환을 유발하는 면역 반응의 핵심 분자인 인터류킨 15(IL-15)를 억제하는 방식으로 작용합니다. TEV-53408은 현재 2a상 임상시험을 통해 안전성과 유효성을 평가하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 셀리악병 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업 분석
• 세계의 셀리악병 시장 : 성장률 분석
• 세계의 셀리악병 시장 실적 : 규모와 성장, 2019-2024년
• 세계의 셀리악병 시장 예측 : 규모와 성장, 2024-2029년, 2034년
• 세계의 셀리악병 : 총 잠재 시장 규모(TAM)

제6장 시장 세분화

• 세계의 셀리악병 시장 : 치료별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 인플릭시맙
• 라라조타이드 아세테이트
• 무글루텐 다이어트
• 기타 치료
• 세계의 셀리악병 시장 : 투여 경로별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 경구
• 비경구
• 세계의 셀리악병 시장 : 최종사용자별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 병원
• 재택의료
• 기타
• 세계의 셀리악병 시장, 인플릭시맙 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 바이오시밀러 인플릭시맙
• 브랜드 이름 인플릭시맙
• 정맥내 투여
• 병원에서의 사용
• 세계의 셀리악병 시장, 라라조타이드 아세테이트 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 임상 검사 단계 제품
• 경구 캡슐 제제
• 성인 셀리악병 환자
• 소아 연구 용도
• 단독요법과 병용요법
• 세계의 셀리악병 시장, 무글루텐 다이어트 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 무글루텐 포장 식품
• 무글루텐 베이커리 제품
• 무글루텐 스낵
• 무글루텐 식이보충제
• 무글루텐 음료
• 세계의 셀리악병 시장, 기타 치료 하위 세분화, 유형별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 코르티코스테로이드
• 면역억제제
• 효소 요법
• 단클론항체
• 프로바이오틱스와 마이크로바이옴 모듈레이터

제7장 지역별·국가별 분석

• 세계의 셀리악병 시장 : 지역별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년
• 세계의 셀리악병 시장 : 국가별, 실적과 예측, 2019-2024년, 2024-2029년, 2034년

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 셀리악병 시장 : 경쟁 구도
• 셀리악병 시장 : 기업 개요
  • Pfizer Inc.
  • Sanofi SA
  • Novartis AG
  • Takeda Pharmaceutical Company Ltd.
  • Chugai Pharmaceutical Co. Ltd.

제31장 기타 주요 기업과 혁신적 기업

• Dr Falk Pharma GmbH
• Theriva Biologics Inc.
• Equillium Inc.
• Immunic Inc.
• Barinthus BIoTherapeutics Plc
• Allero Therapeutics
• Anokion SA
• Mozart Therapeutics
• ImmunogenX
• Topas Therapeutics GmbH
• Parvus Therapeutics Inc.
• AMYRA BIoTech AG
• Provention Limited
• Precigen Inc.
• Zedira GmbH

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 전략

• 셀리악병 시장, 2029년 : 새로운 기회를 제공하는 국가
• 셀리악병 시장, 2029년 : 새로운 기회를 제공하는 부문
• 셀리악병 시장, 2029년 : 성장 전략
  • 시장 동향에 의한 전략
  • 경쟁 전략

제36장 부록

ksm

영문 목차

영문목차

Celiac disease is an autoimmune condition in which the ingestion of gluten triggers an immune response that damages the small intestine, resulting in malabsorption and a range of symptoms. Diagnosis is typically confirmed through blood tests and intestinal biopsy, and the only effective treatment is a lifelong gluten-free diet to promote intestinal healing and prevent complications.

The primary treatments for celiac disease include infliximab, larazotide acetate, gluten-free diets, and other options. Infliximab is a monoclonal antibody that reduces inflammation by inhibiting tumor necrosis factor-alpha (TNF-a). It can be administered via oral or parenteral routes and is used across various settings, including hospitals, home care, and other healthcare facilities.

The celiac disease market research report is one of a series of new reports from The Business Research Company that provides celiac disease market statistics, including celiac disease industry global market size, regional shares, competitors with a celiac disease market share, detailed celiac disease market segments, market trends and opportunities, and any further data you may need to thrive in the celiac disease industry. This celiac disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The celiac disease market size has grown rapidly in recent years. It will grow from $0.71 billion in 2024 to $0.78 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. Growth during the historic period can be attributed to the increasing prevalence of celiac disease, greater awareness of gluten-related disorders, rising research funding for autoimmune conditions, a surge in food allergies and sensitivities, and a growing emphasis on consumer health consciousness.

The celiac disease market size is expected to see rapid growth in the next few years. It will grow to $1.15 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The projected growth in the forecast period can be attributed to the increasing demand for personalized medicine, expansion of healthcare infrastructure, growing need for nutritional counseling services, rising rates of pediatric diagnoses, and a greater focus on early-life screening and preventive measures. Key trends expected during this period include wider availability of diagnostic testing, advancements in genetic testing technologies, enhanced screening protocols in primary care, innovations in ELISA and serological testing methods, and the adoption of non-invasive diagnostic approaches.

The expansion of personalized medicine is expected to contribute significantly to the growth of the celiac disease market in the coming years. Personalized medicine is a healthcare approach that tailors medical treatment to an individual's genetic makeup, environment, and lifestyle. The rising demand for personalized medicine is driven by the growing accessibility of genetic testing, which facilitates more accurate diagnoses and personalized treatment plans based on individual patient profiles. In the context of celiac disease, personalized medicine enables precise identification of genetic markers and specific immune responses, resulting in more targeted and effective treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the FDA approved 16 personalized therapies for rare diseases in 2023, up from 6 in 2022. Thus, the growth of personalized medicine is expected to propel the celiac disease market forward.

Leading companies in the celiac disease market are concentrating on the development of advanced therapies, such as anti-interleukin-15 (IL-15) antibodies, to minimize tissue damage by regulating excessive immune cell activity. Anti-interleukin-15 (IL-15) antibodies are targeted proteins that block the action of the IL-15 cytokine, thereby helping to modulate immune responses and reduce inflammation. For example, in May 2025, Teva Pharmaceutical Industries, a pharmaceutical company based in Israel, announced that the U.S. Food and Drug Administration had granted Fast Track designation to TEV-53408, an investigational anti-interleukin-15 (IL-15) antibody. This monoclonal antibody is being developed for patients with celiac disease who continue to experience symptoms despite adhering to a gluten-free diet. It works by inhibiting interleukin-15 (IL-15), a key molecule responsible for triggering the immune response that causes intestinal damage in celiac disease. TEV-53408 is currently being evaluated in a Phase 2a clinical trial to assess its safety and efficacy.

In May 2025, Targeted Genomics, a US-based company specializing in celiac disease genetics and wellness, entered into a partnership with OraSure Technologies to provide direct-to-consumer (DTC) genetic testing for celiac disease. This collaboration allows Targeted Genomics to work alongside an experienced industry leader to advance their mission. The partnership reinforces their goal of delivering genetic risk information directly to individuals who are proactive about their health. OraSure Technologies is a US-based company that offers diagnostic solutions for celiac disease.

Major players in the celiac disease market are Pfizer Inc., Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Ltd., Chugai Pharmaceutical Co. Ltd., Dr Falk Pharma GmbH, Theriva Biologics Inc., Equillium Inc., Immunic Inc., Barinthus Biotherapeutics Plc, Allero Therapeutics, Anokion SA, Mozart Therapeutics, ImmunogenX, Topas Therapeutics GmbH, Parvus Therapeutics Inc., AMYRA Biotech AG, Provention Limited, Precigen Inc., Zedira GmbH, AnTolRx Inc., Nemysis Ltd., Entero Therapeutics Inc.

North America was the largest region in the celiac disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in celiac disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the celiac disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The celiac disease market consists of revenues earned by entities by providing services such as diagnostic testing services, histopathology services, dietary consultation, nutrition counseling, and food certification. The market value includes the value of related goods sold by the service provider or included within the service offering. The celiac disease market also includes sales of gluten-free foods, diagnostic test kits, nutritional supplements, gluten detection devices, and probiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Celiac Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on celiac disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for celiac disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The celiac disease market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Infliximab; Larazotide Acetate; Gluten Free Diet; Other Treatments
• 2) By Route Of Administration: Oral; Parenteral
• 3) By End Users: Hospitals; Homecare; Other End-Users
• Subsegments:
• 1) By Infliximab: Biosimilar Infliximab; Branded Infliximab; Intravenous Administration; Hospital-Based Usage; Off-Label Use In Refractory Celiac Disease;
• 2) By Larazotide Acetate: Clinical Trial Phase Products; Oral Capsule Formulation; Adult Celiac Patients; Pediatric Investigational Use; Monotherapy And Combination Therapy
• 3) By Gluten Free Diet: Packaged Gluten-Free Foods; Gluten-Free Bakery Products; Gluten-Free Snacks; Gluten-Free Nutritional Supplements; Gluten-Free Beverages
• 4) By Other Treatments: Corticosteroids; Immunosuppressive Drugs; Enzyme Therapies; Monoclonal Antibodies; Probiotics And Microbiome Modulators
• Companies Mentioned: Pfizer Inc.; Sanofi SA; Novartis AG; Takeda Pharmaceutical Company Ltd.; Chugai Pharmaceutical Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Celiac Disease Market Characteristics

3. Celiac Disease Market Trends And Strategies

4. Celiac Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Celiac Disease Growth Analysis And Strategic Analysis Framework

• 5.1. Global Celiac Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Celiac Disease Market Growth Rate Analysis
• 5.4. Global Celiac Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Celiac Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Celiac Disease Total Addressable Market (TAM)

6. Celiac Disease Market Segmentation

• 6.1. Global Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Infliximab
• Larazotide Acetate
• Gluten Free Diet
• Other Treatments
• 6.2. Global Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• 6.3. Global Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Other End-Users
• 6.4. Global Celiac Disease Market, Sub-Segmentation Of Infliximab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biosimilar Infliximab
• Branded Infliximab
• Intravenous Administration
• Hospital-Based Usage
• 6.5. Global Celiac Disease Market, Sub-Segmentation Off-Label Use In Refractory Celiac Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Of Larazotide Acetate, By Type
• Clinical Trial Phase Products
• Oral Capsule Formulation
• Adult Celiac Patients
• Pediatric Investigational Use
• Monotherapy and Combination Therapy
• 6.6. Global Celiac Disease Market, Sub-Segmentation Of Gluten Free Diet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Packaged Gluten-Free Foods
• Gluten-Free Bakery Products
• Gluten-Free Snacks
• Gluten-Free Nutritional Supplements
• Gluten-Free Beverages
• 6.7. Global Celiac Disease Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroids
• Immunosuppressive Drugs
• Enzyme Therapies
• Monoclonal Antibodies
• Probiotics And Microbiome Modulators

7. Celiac Disease Market Regional And Country Analysis

• 7.1. Global Celiac Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Celiac Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Celiac Disease Market

• 8.1. Asia-Pacific Celiac Disease Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Celiac Disease Market

• 9.1. China Celiac Disease Market Overview
• 9.2. China Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Celiac Disease Market

• 10.1. India Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Celiac Disease Market

• 11.1. Japan Celiac Disease Market Overview
• 11.2. Japan Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Celiac Disease Market

• 12.1. Australia Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Celiac Disease Market

• 13.1. Indonesia Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Celiac Disease Market

• 14.1. South Korea Celiac Disease Market Overview
• 14.2. South Korea Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Celiac Disease Market

• 15.1. Western Europe Celiac Disease Market Overview
• 15.2. Western Europe Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Celiac Disease Market

• 16.1. UK Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Celiac Disease Market

• 17.1. Germany Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Celiac Disease Market

• 18.1. France Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Celiac Disease Market

• 19.1. Italy Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Celiac Disease Market

• 20.1. Spain Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Celiac Disease Market

• 21.1. Eastern Europe Celiac Disease Market Overview
• 21.2. Eastern Europe Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Celiac Disease Market

• 22.1. Russia Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Celiac Disease Market

• 23.1. North America Celiac Disease Market Overview
• 23.2. North America Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Celiac Disease Market

• 24.1. USA Celiac Disease Market Overview
• 24.2. USA Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Celiac Disease Market

• 25.1. Canada Celiac Disease Market Overview
• 25.2. Canada Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Celiac Disease Market

• 26.1. South America Celiac Disease Market Overview
• 26.2. South America Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Celiac Disease Market

• 27.1. Brazil Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Celiac Disease Market

• 28.1. Middle East Celiac Disease Market Overview
• 28.2. Middle East Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Celiac Disease Market

• 29.1. Africa Celiac Disease Market Overview
• 29.2. Africa Celiac Disease Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Celiac Disease Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Celiac Disease Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Celiac Disease Market Competitive Landscape And Company Profiles

• 30.1. Celiac Disease Market Competitive Landscape
• 30.2. Celiac Disease Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Takeda Pharmaceutical Company Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Chugai Pharmaceutical Co. Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Celiac Disease Market Other Major And Innovative Companies

• 31.1. Dr Falk Pharma GmbH
• 31.2. Theriva Biologics Inc.
• 31.3. Equillium Inc.
• 31.4. Immunic Inc.
• 31.5. Barinthus Biotherapeutics Plc
• 31.6. Allero Therapeutics
• 31.7. Anokion SA
• 31.8. Mozart Therapeutics
• 31.9. ImmunogenX
• 31.10. Topas Therapeutics GmbH
• 31.11. Parvus Therapeutics Inc.
• 31.12. AMYRA Biotech AG
• 31.13. Provention Limited
• 31.14. Precigen Inc.
• 31.15. Zedira GmbH

32. Global Celiac Disease Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Celiac Disease Market

34. Recent Developments In The Celiac Disease Market

35. Celiac Disease Market High Potential Countries, Segments and Strategies

• 35.1 Celiac Disease Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Celiac Disease Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Celiac Disease Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료